| Change from baseline | Treatment-related | |
---|---|---|---|
 | Artz | Durolane | difference |
(5 × 2.5 ml) | (1 × 3 ml, 4 × sham) | (Durolane – Artz) | |
( n  = 158) | ( n  = 161) |  | |
Pain a | |||
Week 18 | Â | Â | Â |
 LSM (95% CI) | −5.87 (−6.23; −5.52) | −5.97 (−6.32; −5.61) | −0.09 (−0.58; 0.39) |
  P value | <0.0001 | <0.0001 | 0.7034 |
Week 26 | Â | Â | Â |
 LSM (95% CI) | −6.05 (−6.39; −5.71) | −6.15 (−6.49; −5.81) | −0.10 (−0.56; 0.37) |
  P value | <0.0001 | <0.0001 | 0.6783 |
Physical function a | |||
Week 18 | Â | Â | Â |
 LSM (95% CI) | −12.10 (−12.95; −11.26) | −12.75 (−13.60; −11.91) | −0.65 (−1.81; 0.51) |
  P value | <0.0001 | <0.0001 | 0.2718 |
Week 26 | Â | Â | Â |
 LSM (95% CI) | −12.58 (−13.39; −11.77) | −13.16 (−13.97; −12.35) | −0.58 (−1.69; 0.53) |
  P value | <0.0001 | <0.0001 | 0.3054 |
Global evaluation b | |||
Week 18 | Â | Â | Â |
 LSM (95% CI) | 2.55 (2.33; 2.77) | 2.70 (2.48; 2.92) | 0.15 (−0.15; 0.45) |
  P value | <0.0001 | <0.0001 | 0.3319 |
Week 26 | Â | Â | Â |
 LSM (95% CI) | 2.67 (2.45; 2.88) | 2.81 (2.59; 3.02) | 0.14 (−0.16; 0.43) |
  P value | <0.0001 | <0.0001 | 0.3583 |
Knee stiffness a | |||
Week 18 | Â | Â | Â |
 LSM (95% CI) | −1.73 (−1.87; −1.59) | −1.87 (−2.00; −1.73) | −0.14 (−0.33; 0.05) |
  P value | <0.0001 | <0.0001 | 0.1602 |
Week 26 | Â | Â | Â |
 LSM (95% CI) | −1.80 (−1.93; −1.67) | −1.95 (−2.08; −1.82) | −0.15 (−0.33; 0.03) |
  P value | <0.0001 | <0.0001 | 0.1012 |